Summary
Differentiated thyroid carcinomas (in contrast to the rarer anaplastic form) are unusual among human cancers in displaying a remarkably low frequency of p53 mutation and appear to retain wild-type (wt) p53 function as assessed by the response of derived cell lines to DNA damage. Using one such cell line, K1, we have tested the effect of experimental abrogation of p53 function by generating matched sub-clones stably expressing either a neo control gene, a dominant-negative mutant p53 (143ala) or human papilloma virus protein HPV16 E6. Loss of p53 function in the latter two groups was confirmed by abolition of p53-dependent ‘stress’ responses including induction of the cyclin/CDK inhibitor p21WAF1 and G1/S arrest following DNA-damage. In contrast, no change was detected in the phenotype of ‘unstressed’ clones, with respect to any of the following parameters: proliferation rate in monolayer, serum-dependence for proliferation or survival, tumorigenicity, cellular morphology, or tissue-specific differentiation markers. The K1 line therefore represents a ‘neutral’ background with respect to p53 function, permitting the derivation of functionally p53 + or – clones which are not only iso-genic but also iso-phenotypic. Such a panel should be an ideal tool with which to test the p53-dependence of cellular stress responses, particularly the sensitivity to potential therapeutic agents, free from the confounding additional phenotypic differences which usually accompany loss of p53 function. The results also further support the hypothesis that p53 mutation alone is not sufficient to drive progression of thyroid cancer to the aggressive anaplastic form.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Almog, N. & Rotter, V. (1997). Involvement of p53 in cell differentiation and development. Biochim Biophys Acta 133: F1–F27.
Aloni-Grinstein, R., Zan-Bar, I., Alboum, R., Goldfinger, N. & Rotter, V. (1993). Wild-type p53 functions as a control protein in the differentiation pathway of the B-cell lineage. Oncogene 8: 3297–3305.
Aloni-Grinstein, R., Schwartz, D. & Rotter, V. (1995). Accumulation of wild-type p53 protein upon γ irradiation induces a G2arrest-dependent immunoglobulin κ light chain gene expression. EMBO J 14: 1392–1401.
Baker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K. V. & Vogelstein, B. (1990). Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249: 912–915.
Barnes, D. M., Dublin, E. A., Fisher, C. J., Levison, D. A. & Millis, R. R. (1993). Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Human Pathol 24: 469–476.
Battista, S., Martelli, M. L., Fedele, M., Chiappetta, G., Trapasso, F., De Vita, G., Battaglia, C., Santoro, M., Viglietto, G., Fagin, J. A. & Fusco, A. (1995). A mutated p53 gene alters thyroid cell differentiation. Oncogene 11: 2029–2037.
Bi, S., Barton, C. M., Lemoine, N. R., Cross, N. C. P. & Goldman, J. M. (1994). Retroviral transduction of Philadelphia-positive chronic myeloid leukaemia cells with a human mutant p53 cDNA and its effect on in vitro proliferation. Exp Hematol 22: 95–99.
Blaydes, J. P., Schlumberger, M., Wynford-Thomas, D. & Wyllie, F. S. (1995). Interaction between p53 and TGFb1 in control of epithelial cell proliferation. Oncogene 10: 307–317.
Bond, J. A., Dawson, T., Lemoine, N. R. & Wynford-Thomas, D. (1992). Effect of serum growth factors and phorbol ester on growth and survival of human thyroid epithelial cells expressing mutant ras. Mol Carcinogen 5: 129–135.
Bond, J. A., Blaydes, J. P., Rowson, J., Haughton, M. F., Smith, J. R., Wynford-Thomas, D. & Wyllie, F. S. (1995). Mutant p53 rescues human diploid cells from senescence without inhibiting the induction of SDI1/WAF1. Cancer Res 55: 2404–2409.
Bond, J. A., Ness, G. O., Rowson, J., Ivan, M., White, D. & Wynford-Thomas, D. (1996). Spontaneous de-differentiation correlates with extended lifespan in transformed thyroid epithelial cells: An epigenetic mechanism of tumour progression? Int J Cancer 67: 563–572.
Brash, D. E., Reddel, R. R., Quanrad, M., Yang, K., Farrell, M. P. & Harris, C. C. (1987). Strontium phosphate transfection of human cells in primary culture: stable expression of the Simian virus 40 large-T-Antigen gene in primary human bronchial epithelial cells. Mol Cell Biol 7: 2031–2034.
Brenner, L., Munozantonia, T., Vellucci, V. F., Zhou, Z-L & Reiss, M. (1994). Wild-type p53 tumour suppressor gene restores differentiation of human squamous carcinoma cells but not the response to transforming growth factor-beta. Cell Growth Diff 4: 993–1004.
Brocas, H., Christophe, D., Pohl, V. & Vassart, G. (1982). Cloning of human thyroglobulin complementary DNA. FEBS Lett 137: 189–192.
Burns, J. S., Lemoine, L., Lemoine, N. R., Williams, E. D. & Wynford-Thomas, D. (1989). Thyroid epithelial cell transformation by a retroviral vector expressing SV40 large T. Br J Cancer 59: 755–760.
Carcangiu, M. L., Steeper, T., Zampi, G. & Rosai, J. (1985). Anaplastic thyroid carcinoma. Am J Cell Pathol 83: 135–158.
Challeton, C., Branea, F., Schlumberger, M., Gaillard, N., DeVathaire, F., Badie, C., Antonini, P. & Parmentier, C. (1997). Characterisation and radiosensitivity at high or low dose rate of four cell lines derived from human thyroid tumours. Int J Radiat Oncol Biol Physics 37: 163–169.
Diller, L., Kassel, J., Nelson, C. E., Gryka, M. A., Litwak, G., Gebhardt, M., Bressac, B., Ozturk, M., Baker, S. J., Vogelstein, B. & Friend, S. H. (1990). p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol 10: 5772–5781.
Eizenberg, O., Faber-Elman, A., Gottlieb, E., Oren, M., Rotter, V. & Schwartz, M. (1996). p53 plays a regulatory role in differentiation and apoptosis of central nervous system-associated cells. Mol Cell Biol 16: 5178–5185.
El-Deiry, W. S., Harper, J. W., O’Connor, P. M., Velculescu, V. E., Canman, C. E., Jackman, J., Pietenpol, J. A., Burrell, M., Hill, D. E., Wang, Y., Wiman, K. G., Mercer, W. E., Kastan, M. B., Kohn, K. W., Elledge, S. J., Kinzler, K. W. & Vogelstein, B. (1994). WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54: 1169–1174.
Fabbro, D., Di Loreto, C., Beltrami, C. A., Belfiore, A., Di Lauro, R. & Damante, G. (1994). Expression of thyroid-specific transcription factors TTF-1 and PAX-8 in human thyroid neoplasms. Cancer Res 54: 4744–4749.
Fagin, J. A., Matsuo, K., Karmakar, A., Chen, D. L., Tang, S-H & Koeffler, H. P. (1993). High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91: 179–184.
Fagin, J. A., S-H, T. Zeki, K., Di Lauro, R., Fusco, A. & Gonsky, R. (1996). Re-expression of thyroid peroxidase in a derivative of an undifferentiated thyroid carcinoma cell line by introduction of wild-type p53. Cancer Res 56: 765–771.
Fan, S., Smith, M. L., Rivet, D. J., Duba, D., Zhan, Q., Kohn, K. W., Fornace, A. J. & O’Connor, P. M. (1995). Disruption of p53 function sensitises breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 55: 1649–1654.
Fearon, E. R. & Vogelstein, B. A. (1990). A genetic model for colorectal tumorigenesis. Cell 61: 759–767.
Feinstein, E., Gale, R. P., Reed, J. & Canaani, E. (1992). Expression of the normal p53 gene induces differentiation of K562 cells. Oncogene 7: 1853–1857.
Forrester, K., Lupold, S. E., Ott, V. L., Chay, C. H., Band, V., Wang, X. W. & Harris, C. C. (1995). Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent. Oncogene 10: 2103–2111.
Friedlander, P., Haupt, Y., Prives, C. & Oren, M. (1996). A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Mol Cell Biol 16: 4961–4971.
Fujimoto, K., Yamada, Y., Okajima, E., Kakizoe, T., Sasaki, H., Sugimura, T. & Terada, M. (1992). Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res 52: 1393–1398.
Greenblatt, M. S., Bennett, W. P., Hollstein, M. & Harris, C. C. (1994). Mutations in the p53 tumour suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855–4878.
Guazzi, S., Price, M., De Felice, M., Damante, G., Mattei, M-G & Di Lauro, R. (1990). Thyroid nuclear factor 1 (TTF1) contains a homeodomain and displays a novel DNA binding specificity. EMBO J 9: 3631–3639.
Halbert, C. L., Demers, G. W. & Galloway, D. A. (1991). The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J Virol 65: 473–478.
Halevy, O. (1993). p53 gene is up-regulated during skeletal muscle cell differentiation. Biochem Biophy Res Commun 192: 714–719.
Harlow, E., Crawford, L. V., Pim, D. C. & Williamson, N. M. (1981). Monoclonal antibodies specific for simian virus 40 tumour antigens. J Virol 39: 861–869.
Hsu, T. C., Johnston, D. A., Cherry, L. M., Ramkisson, D., Schantz, S. P., Jessup, J. H., Winn, R. J., Shirley, L. & Furlong, C. (1989). Sensitivity to genotoxic effects of bleomycin in humans; possible relationship to environmental carcinogenesis. Int J Cancer 43: 403–409.
Ito, T., Seyama, T., Mizuno, T., Tsuyama, N., Hayashi, T., Hayashi, Y., Dohi, K., Nakamura, N. & Akiyama, M. (1992). Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res 52: 1369–1371.
Johnson, P., Gray, D., Mowat, M. & Benchimol, S. (1991). Expression of wild-type p53 is not compatible with continued growth of p53-negative tumour cells. Mol Cell Biol 11: 1–11.
Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B. & Craig, R. W. (1991). Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304–6311.
Kemp, C. J., Donehower, L. A., Bradley, A. & Balmain, A. (1993). Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumours. Cell 74: 813–822.
Lavigeur, A., Maltby, V., Mock, D., Rossant, J., Pawson, T. & Bernstein, A. (1989). High incidence of lung, bone and lymphoid tumours in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol Cell Biol 9: 3982–3991.
Libert, F., Ruel, J., Ludgate, M., Swillens, S., Alexander, N., Vassart, G. & Dinsart, C. (1987). Complete nucleotide sequence of the human thyroperoxidase-microsomal antigen cDNA. Nucleic Acids Res 15: 6735
Libert, F., Lefort, A., Gerard, C., Parmentier, M., Perret, J., Ludgate, M., Dumont, J. E. & Vassart, G. (1989). Cloning, sequencing and expression of the human thyrotropin (TSH) receptor: evidence for binding of autoantibodies. Biochem Biophys Res Commun 165: 1250–1255.
Ludwig, R. L., Bates, S. & Vousden, K. (1996). Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol Cell Biol 66: 4952–4960.
McIlwrath, A. J., Vasey, P. A., Ross, G. M. & Brown, R. (1994). Cell cycle arrests and radiosensitivity of human tumour cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Res 54: 3718–3722.
Michalovitz, D., Halevy, O. & Oren, M. (1991). p53 mutations: gains or losses? J Cell Biochem 45: 22–29.
Moretti, F., Farsetti, A., Soddu, S., Misiti, S., Crescenzi, M., Filetti, S., Andreoli, M., Sacchi, A. & Pontecorvi, A. (1997). p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells. Oncogene 14: 729–740.
Navone, N. M., Troncoso, P., Pisters, L. L., Goodrow, T. L., Palmer, J. L., Nichols, W. W., Von Eschenbach, A. C. & Conti, C. J. (1993). p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 85: 1657–1669.
O’Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., Friend, S., Fornace, A. J. & Kohn, K. W. (1997). Characterisation of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57: 4285–4300.
Poleev, A., Fickenscher, H., Mundlos, S., Winterpacht, A., Zabel, B., Fidler, A., Gruss, P. & Plachov, D. (1992). PAX8, a human paired box gene: isolation and expression in developing thyroid, kidney and Wilms’ tumors. Development 116: 611–623.
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J. & Howley, P. M. (1990). The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129–1136.
Shaulsky, G., Goldfinger, N., Peled, A. & Rotter, V. (1991). Involvement of wild-type p53 in pre-B-cell differentiation in vitro. Proc Natl Acad Sci USA 88: 8982–8986.
Soddu, S., Blandino, G., Citro, G., Scardigli, R., Piaggio, G., Ferber, A., Calabretta, B. & Sacchi, A. (1994). Wild-type p53 gene expression induces granulocytic differentiation of HL-60 cells. Blood 83: 2230–2237.
Soddu, S., Blandino, G., Scardigli, R., Coen, S., Marchetti, A., Rizzo, M. G., Bossi, G., Cimino, L., Crescenzi, M. & Sacchi, A. (1996). Interference with p53 protein inhibits hematopoietic and muscle differentiation. J Cell Biol 134: 193–204.
Southern, P. J. & Berg, P. (1982). Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter. J Mol App Genet 1: 327–341.
Weinberg, W. C., Azzoli, C. G., Chapman, K., Levine, A. J. & Yuspa, S. H. (1995). p53-mediated transcriptional activity increases in differentiating epidermal keratinocytes in association with decreased p53 protein. Oncogene 10: 2271–2279.
Weinstein, J. N., Myers, T. G., O’Connor, P. M. & Friend, S. H. (1997). An information-intensive approach to the molecular pharmacology of cancer. Science 275: 343–349.
Williams, A. C., Miller, J. C., Collard, T. J., Bracey, T. C., Cosulich, S. & Paraskeva, C. (1995). Mutant p53 is not fully dominant over endogenous wild type p53 in a colorectal adenoma cell line as demonstrated by induction of MDM2 protein and retention of a p53 dependent G1 arrest after γ irradiation. Oncogene 11: 141–149.
Williams, D. W. & Williams, E. D. (1989). The pathology of follicular thyroid epithelial tumours. In Wynford-Thomas D, Williams ED (eds) Thyroid Tumours: Molecular Basis of Pathogenesis, pp. 57–65, Churchill Livingstone: Edinburgh
Wright, P. A., Lemoine, N. R., Goretzki, P. E., Wyllie, F. S., Bond, J., Hughes, C., Roher, H-D, Williams, E. D. & Wynford-Thomas, D. (1991). Mutation of the p53 gene in a differentiated human thyroid carcinoma cell line, but not in primary thyroid tumours. Oncogene 6: 1693–1697.
Wyllie, F. S., Lemoine, N. R., Williams, E. D. & Wynford-Thomas, D. (1989). Structure and expression of nuclear oncogenes in multi-stage thyroid tumorigenesis. Br J Cancer 60: 561–565.
Wyllie, F. S., Lemoine, N. R., Barton, C. M., Dawson, T., Bond, J. A. & Wynford-Thomas, D. (1993). Direct growth stimulation of normal human epithelial cells by mutant p53. Mol Carcinogen 7: 83–88.
Wyllie, F. S., Haughton, M. F., Blaydes, J. P., Schlumberger, M. & Wynford-Thomas, D. (1995). Evasion of p53-mediated growth control occurs by three alternative mechanisms in transformed thyroid epithelial cells. Oncogene 10: 49–59.
Wynford-Thomas, D. (1993). Molecular genetics of thyroid cancer. Trends Endocrinol Metab 4: 224–232.
Wynford-Thomas, D. (1996). p53: guardian of cellular senescence. J Pathol 180: 118–121.
Wynford-Thomas, D., Bond, J. A., Wyllie, F. S., Burns, J., Williams, E. D., Jones, T., Sheer, D. & Lemoine, N. R. (1990). Conditional immortalisation of human thyroid epithelial cells: a tool for analysis of oncogene action. Mol Cell Biol 10: 5365–5377.
Wynford-Thomas, D., Jones, C. J. & Wyllie, F. S. (1996). The tumour suppressor gene p53 as a regulator of proliferative life-span and tumour progression. Biol Signals 5: 139–153.
Ziegler, A., Jonason, A. S., Leffell, D. J., Simon, J. A., Sharma, H. W., Kimmelman, J., Remington, L., Jacks, T. & Brash, D. E. (1994). Sunburn and p53 in the onset of skin cancer. Nature 372: 773–777.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Wyllie, F., Haughton, M., Rowson, J. et al. Human thyroid cancer cells as a source of iso-genic, iso-phenotypic cell lines with or without functional p53. Br J Cancer 79, 1111–1120 (1999). https://doi.org/10.1038/sj.bjc.6690177
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690177
Keywords
This article is cited by
-
PAX8 promotes tumor cell growth by transcriptionally regulating E2F1 and stabilizing RB protein
Oncogene (2011)
-
p53 promotes adenoviral replication and increases late viral gene expression
Oncogene (2006)
-
Telomere erosion triggers growth arrest but not cell death in human cancer cells retaining wild-type p53: implications for antitelomerase therapy
Oncogene (2004)
-
Delayed expression of apoptosis in human lymphoma cells undergoing low-dose taxol-induced mitotic stress
British Journal of Cancer (2003)
-
Tissue-selective therapy of cancer
British Journal of Cancer (2003)